Approximately 60% to 70% of patients aged 18 to 65 years will achieve a complete remission, but just 30.5% of these patients ...
Recent studies highlight the potential of minimal residual disease (MRD) testing to influence treatment decisions in multiple ...
The FDA has approved the biologics license application (BLA) for the subcutaneous (SC) administration of pembrolizumab ...
Berry and colleagues from the Institute for Healthcare Improvement and Henry Ford Health Detroit argue that deep, ...
Following its Type A meeting with the FDA, Replimune reported that a forward pathway “has not been determined” to obtain ...
ADG126 is a novel anti–CTLA-4 agent incorporating protease-cleavable masking technology that enables tumor-specific ...
Carotuximab (ENV105) plus standard-of-care hormone therapy apalutamide (Erleada) demonstrated a progression-free survival ...
FDA fast track is intended to expedite the development of therapies that fill serious unmet medical needs. With this ...
In this installment of Chief Insights in Oncology, John M. Burke, MD, co-editor in chief of Targeted Therapies in Oncology, discusses his column from the September II 2025 issue.
Through a search of electronic health records from the IKnowMed clinical oncology database (McKesson, Houston, TX, USA) the ...
In recognition of September as Prostate Cancer Awareness Month, Daniel Petrylak, MD, professor of oncology and urology at ...
Sacituzumab govitecan is comprised of a humanized antitrophoblast cell-surface antigen 2 monoclonal antibody coupled to SN-38 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback